Psilocybin for Treatment-Resistant OCD: A Randomized Controlled Trial
January 15, 2026 Benjamin Kelmendi, Thomas G. Adams, Terence H. W. Ching et al. preprint
Background: Obsessive-compulsive disorder (OCD) affects 2-3% of the population worldwide. 40-60% of patients do not respond to first-line interventions. We evaluated the efficacy and safety of a single dose of psilocybin in patients with treatment-resistant OCD.Methods: In this phase 2, randomized, double-blind trial, we randomly assigned 28 adults with treatment-resistant OCD to receive a...
DOI: 10.31234/osf.io/atfum_v1 (opens in new tab)
Psilocybin
Major depressive disorder
Adverse effect
Randomized controlled trial
+8